A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.
The University of Michigan Health System has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.
University of Michigan Comprehensive Cancer Center researchers Maha Hussain, M.D., and Arul Chinnaiyan, M.D., Ph.D., received two of six grant awards from the Movember-Prostate Cancer Foundation Challenge.
Kathleen A. Cooney, M.D. of the University of Michigan Comprehensive Cancer Center, led this research effort which may may provide clues on prostate cancer development and who may need earlier screening.
A research study led by Maha Hussain, MD, associate director of clinical research at the University of Michigan Comprehensive Cancer Center has found that the survival rate for African American men is now comparable to caucasians when it comes to prostate cancer.
Over men 1200 men with metastatic, hormone-sensitive prostate cancer were given intermittent androgen-deprivation (AD) therapy after seven months of androgen deprivation. The results show intermittent hormone therapy offers some quality-of-life benefits, but lower overall survival.